Clinical trial for comparision of Anagrelid retard versus placebo in subjects with Essential Thrombocythaemia
- Conditions
- male and female at risk subjects with Essential ThrombocythaemiaMedDRA version: 17.0Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Registration Number
- EUCTR2009-017095-24-BG
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 240
• Willing and able to give written informed consent prior to any study specific procedures and able to comply with this protocol
• Male or female subjects aged between 18 and 60 years,
• Confirmed diagnosis of ET according to WHO-criteria (2008) including assessment of JAK-2 status.
• Presence of predisposing risk factors for ET related events confirmed by clinical or laboratory results:
- Platelet count < 1.000 G/L
additionally at least ONE of the following criteria has to be fulfilled:
- Subjects aged between 40 and 60 years
or
- Subjects with ET and disease duration > 3 years (Diagnosis of ET has to be at least 3 years ago and confirmed at time of screening)
or
- Subjects with ONE of the following risk factors for thrombotic complications:
a)JAK- 2 positivity, b)Protein C and/or Protein S deficiency, c)Antithrombin III deficiency, d)Factor V Leiden or Prothrombin mutation, e)Cardiovascular risk factors: Essential hypertension; Smoking (>5 cigarettes/d), Obesity (BMI>30), Cholesterol (HDL/LDL ratio < 4); Hormone replacement therapy; hormonal contraception
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 280
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
• Diagnosis of any other myeloproliferative disorder
• High-risk status (age > 60 years, platelet count = 1.000 G/L, increase of platelet count > 300 G/L within 3 month, history of thrombotic/haemorhagic or ischemic complications).
• Any known cause for a secondary thrombocytosis
• Previous or current treatment of ET with cytoreductive therapy
• Diagnosis of any malignancy, apart from ET, within the last 3 years
• Known or suspected intolerance to the investigational products
• Known or suspected congestive heart failure
• WBC = 15 G/L
• Severe renal impairment (creatinine clearance <30 ml/min)
• Severe liver impairment (ALT or AST >5 times normal)
• Clinically significant abnormal laboratory values (excluding markers of essential thrombocythaemia)
• Poorly controlled diabetes mellitus
• Infection with hepatitis B, hepatitis C or HIV
• Subjects with a history of drug/alcohol abuse (within the previous 2 years)
• Participation in another investigational study within 6 months prior to enrolment or for a longer duration if specified in local regulations
• Women of childbearing potential with inadequate contraception
• Pregnant or lactating women (pregnancy test to be assessed within 7 days prior to study treatment start)
• Any significant psychiatric disorder that, in the opinion of the investigator, might prohibit the understanding and giving of informed consent or that might prevent the subject from completing the trial.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.